These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
979 related items for PubMed ID: 8899189
41. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Ball E, Cook D, Andresen S, Kuczkowski E, Bolwell B. Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282 [Abstract] [Full Text] [Related]
42. Allogeneic bone marrow transplantation from partially mismatched related donors as therapy for primary induction failure acute myeloid leukemia. Chiang KY, Van Rhee F, Godder K, Bridges K, Adams S, Mehta J, Henslee-Downey PJ. Bone Marrow Transplant; 2001 Mar; 27(5):507-10. PubMed ID: 11313684 [Abstract] [Full Text] [Related]
43. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. Matsuyama T, Kojima S, Kato K. Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791 [Abstract] [Full Text] [Related]
44. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide. Bostrom B, Weisdorf DJ, Kim T, Kersey JH, Ramsay NK. Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007 [Abstract] [Full Text] [Related]
45. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD. Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494 [Abstract] [Full Text] [Related]
46. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation. Cesaro S, Meloni G, Messina C, Pillon M, Proglia A, Lanino E, Caniggia M, Bagnulo S, Pession A, Locatelli F, Italian Pediatric Group for Bone Marrow Transplantation. Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930 [Abstract] [Full Text] [Related]
47. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM). Jourdan E, Maraninchi D, Reiffers J, Gluckman E, Rio B, Jouet JP, Michallet M, Molina L, Archimbaud E, Harousseau JL, Ifrah N, Attal M, Guilhot F, Kuentz M, Guyotat D, Pico JL, Dauriac C, Legros M, Dreyfus F, Bordigoni P, Leblond V, Gratecos N, Varet B, Auzanneau C, Blaise D. Bone Marrow Transplant; 1997 May; 19(9):875-81. PubMed ID: 9156260 [Abstract] [Full Text] [Related]
48. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. Jabro G, Koc Y, Boyle T, Schenkein DP, Ravalese J, Wazer D, Miller KB. Biol Blood Marrow Transplant; 1999 May; 5(3):173-9. PubMed ID: 10392963 [Abstract] [Full Text] [Related]
49. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants. Al-Kasim FA, Thornley I, Rolland M, Lau W, Tsang R, Freedman MH, Saunders EF, Calderwood S, Doyle JJ. Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456 [Abstract] [Full Text] [Related]
50. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F. Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [Abstract] [Full Text] [Related]
51. [Effectiveness of allogeneic bone marrow transplantation in patients with acute leukemia in complete remission and in patients with chronic myeloid leukemia during the chronic phase]. Liubimova LS, Savchenko VG, Mendeleeva LP, Kliasova GA, Gribanova EO, Demidova IA, Gal'tseva IV, Kuz'mina LA, Momotiuk KS, Kuliev RG. Ter Arkh; 1999 Mar; 71(7):27-32. PubMed ID: 10481864 [Abstract] [Full Text] [Related]
52. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients. Aristei C, Aversa F, Raymondi C, Marsella AR, Panizza BM, Perrucci E, Piro F, Maranzano E, Lupattelli M, Martelli MF, Latini P. Cancer J Sci Am; 1996 Mar; 2(6):330-4. PubMed ID: 9166553 [Abstract] [Full Text] [Related]
53. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. Galimberti M, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Giardini C, Gaziev D, Erer B, Ripalti M, Rapa S. Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089 [Abstract] [Full Text] [Related]
54. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J. J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801 [Abstract] [Full Text] [Related]
55. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Worth L, Tran H, Petropoulos D, Culbert S, Mullen C, Roberts W, Przepiorka D, Chan K. Bone Marrow Transplant; 1999 Nov 01; 24(9):947-52. PubMed ID: 10556952 [Abstract] [Full Text] [Related]
56. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation. Lemoli RM, Bandini G, Leopardi G, Rosti G, Bonini A, Fortuna A, Rondelli D, Mangianti S, Motta MR, Rizzi S, Tassi C, Cavo M, Remiddi C, Curti A, Conte R, Tura S. Haematologica; 1998 Jan 01; 83(1):48-55. PubMed ID: 9542323 [Abstract] [Full Text] [Related]
57. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Singhal S, Powles R, Treleaven J, Horton C, Swansbury GJ, Mehta J. Bone Marrow Transplant; 1996 Dec 01; 18(6):1049-55. PubMed ID: 8971372 [Abstract] [Full Text] [Related]
58. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia]. Sun J, Meng FY, Liu QF, Xu D, Xu B, Liu XL. Ai Zheng; 2003 Dec 01; 22(12):1321-4. PubMed ID: 14693060 [Abstract] [Full Text] [Related]
59. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N. Bone Marrow Transplant; 1998 Jun 01; 21(11):1079-83. PubMed ID: 9645568 [Abstract] [Full Text] [Related]
60. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J. Bone Marrow Transplant; 2005 Nov 01; 36(9):825-30. PubMed ID: 16151430 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]